Neonatal abstinence syndrome

Current Opinion in Pediatrics

Volumn 24, Issue 2, 2012, Pages

  Jansson, Lauren M ^a   Velez, Martha ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

buprenorphine; drug exposed neonate; maternal drug use; methadone; neonatal abstinence syndrome; serotonin reuptake inhibitor

Indexed keywords

BUPRENORPHINE; CLONIDINE; METHADONE; PHENOBARBITAL;

BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MOTOR PERFORMANCE; PREGNANCY; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84859104176     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834fdc3a     Document Type: Review

References (67)

1. Kellog A, Rose CH, Harms RH, Watson WJ. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol 2011; 204:259; e1-e4.
2. .Jones HE, Kaltenbach K, Heil S, et al. Neonatal abstinence syndrome following methadone or buprenorphine exposure. New Engl J Med 2010; 363:2320-2331. This study reports the results of a large, international, multisite randomized clinical trial employing a double-blind, double-dummy protocol comparing methadone with buprenorphine treatment during pregnancy. Results indicate that, although buprenorphine-treated women were more likely to discontinue treatment, among infants, buprenorphine exposure resulted in reduced requirements for medication to treat NAS and shorter hospital stays.
3. Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know? Am J Addict 2010; 19:73-88.
4. Gwin Mitchell S, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict 2009; 18:346-355.
5. Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011; 31:615-620.
6. Sie SD, Wenninck JMB, van Driel JJ, et al. Maternal use of SRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed 2011. [Epub ahead of print]
7. Pierog S, Chandavasu O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr 1977; 90:630-633. (Pubitemid 8083192)
8. Robe LB, Gromisch DS, Iosub S. Symptoms of neonatal ethanol withdrawal. Curr Alcohol 1981; 8:485-493.
9. Wikner BN, Stiller C, Bergman U, et al. Use of benzodiazepines and benzodiazepine agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1203-1210. (Pubitemid 350120645)
10. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate and the nursing infant. Psychiatr Serv 2002; 53:39-49. (Pubitemid 34038614)
11. Pichini S, Garcia-Algar O. In utero exposure to smoking and newborn neurobehavior: how to assess neonatal withdrawal syndrome? Ther Drug Monit 2006; 28:288-290. (Pubitemid 44314910)
12. Gentile S. On categorizing gestational, birth and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 2010; 15:167-185.
13. Sinclair L. Antipsychotic labels to cite risks to newborns. Psych News 2011; 46:12. http://pn.psychiatryonline.org/content/46/7/12.1.full. [Accessed 10 October 2011]
14. Mayes LC, Carroll KM. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. Subst Use Misuse 1996; 31:241-253. (Pubitemid 26094986)
15. Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75:253-260. (Pubitemid 38993295)
16. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011. [Epub ahead of print]
17. Jansson LM, Di Pietro JA, Elko A, et al. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend (in press).
18. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007; 32:19-25. (Pubitemid 44908840)
19. Lester BM, Tronick E, Nestler E, et al. Behavioral epigenetics. Ann NYAcad Sci 2011; 1226:14-33.
20. Oei JL, Xu HX, Abdel-Latif ME, et al. Dopamine D2 receptor gene polymorphisms in newborn infants of drug-using women. Arch Dis Child Fetal Neonatal Ed 2011. [Epub ahead of print]
21. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65:230-237.
22. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160:173-176. (Pubitemid 43213863)
23. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci 2008; 45:107-113.
24. Field T. Prenatal depression and selective serotonin reuptake inhibitors. Int J Neurosci 2010; 120:163-167.
25. Devlin AM, Brain U, Austin J, Oberlander TF. Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS One 2010; 5:e12201.
26. Lester BM, Padbury JF. Third pathophysiology of prenatal cocaine exposure. Dev Neurosci 2009; 31:23-35. The authors describe a model in which prenatal cocaine exposure affects acute and long-term behavioral regulation of exposed children via altered fetal programming.
27. Salisbury AL, Ponder KL, Padbury JF, Lester BM. Fetal effects of psychoactive drugs. Clin Perinatol 2009; 36:595-619. A comprehensive review of the multiple mechanisms affecting the substanceexposed fetus and infant.
28. Jansson LM, DiPietro JA, Elko A, Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med 2007; 20:677-685. (Pubitemid 47262703)
29. Radtke KM, Ruf M, Gunter HM, et al. Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor psychosocial function. Translational Psychiatry 2011; 1:e21. doi: 10.1038/ tp.2011.21.
30. Velez ML, Montoya ID, Jansson LM, et al. Exposure to violence among substance-dependent pregnant women and their children. J Subst Abuse Treat 2006; 30:31-38. (Pubitemid 41827931)
31. Pluess M, Belsky J. Prenatal programming of postnatal plasticity? Dev Psychopathol 2011; 23:29-38.
32. Saiki T, Lee S, Hannam S, Greenough A. Neonatal abstinence syndrome postnatal ward versus neonatal unit management. Eur J Pediatr 2010; 169: 95-98.
33. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy:comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96:69-78.
34. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82:250-257.
35. Fischer G, Etzersdorfer P, Eder H, et al. Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res 1998; 4 (Suppl 1):32-36. (Pubitemid 28478993)
36. Jansson LM, DiPietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2010; 33:240-243.
37. Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and after dosing with buprenorphine and methadone. Addiction (in press).
38. Jansson LM, Elko A, DiPietro J. Fetal response to maternal methadone administration. Obstet Gynecol 2005; 193:611-617. (Pubitemid 41261452)
39. Gaalema D, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- vs. buprenorphine-exposed neonates. Addiction (in press).
40. Ferreira E, Carceller AM, Agogue A, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119:52-59. (Pubitemid 46397842)
41. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 2006; 293:2372-2383.
42. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants: a pragmatic valuation of its efficacy. Clin Pediatr 1975; 14:592-594.
43. Ostrea E, Chavez C, Strauss M. A study of factors that influence the severity of neonatal withdrawal. J Pediatr 1976; 88:642-645.
44. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2:141-158.
45. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5:47-55.
46. Jones HC. Shorter dosing interval of opiate solution shortens hospital stay for methadone babies. Fam Med 1999; 31:327-330. (Pubitemid 30619069)
47. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010:CD002059.
48. Kraft WK, Dysart K, Greenspan JS, et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011; 106:574-580. A randomized open-label study evaluating the safety and efficacy of sublingual buprenorphine as compared with oral morphine treatment for NAS.
49. Leikin JB, Mackendrick WP, Maloney GE, et al. Use of clonidine in the prevention and management of neonatal abstinence syndrome. Clin Toxicol 2009; 47:551-555.
50. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009; 123:e849-e856.
51. Coyle MG, Ferguson A, LaGasse L, et al. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002; 140:561-564. (Pubitemid 34666726)
52. Velez ML, Jansson LM, Williams E, Schroeder J. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res 2009; 66:704-709.
53. Sapienza JK, Masten AS. Understanding and promoting resilience in children and youth. Curr Opin Psychiatry 2011; 24:267-273.
54. Oberlander TF, Bonaguro RJ, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008; 13:65-73. (Pubitemid 350275180)
55. de Castro A, Jones HE, Johnson RE, Gray TR, et al. Maternal Methadone Dose, Placental Methadone Concentrations, and Neonatal Outcomes. Clin Chem 2011; 57:449-458.
56. de Castro A, Jones HE, Johnson RE, Gray TR, et al. Methadone, Cocaine, Opiates, and Metabolite Disposition in Umbilical Cord and Correlations to Maternal Methadone Dose and Neonatal Outcomes. Ther Drug Monit 2011; 33:443-452.
57. Gomez SO, Lopez-Vilchez MA, Ledo FD, Ponce EC, et al. Use of illicit drugs over gestation and their neonatal impact. Comparison between periods 1982-1988 and 2002- 2008 [Spanish]. Med Clin (Barc) 2011; 136:423-430.
58. Gray TR, Choo RE, Concheiro M, Williams E, et al. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction 2010; 105:2151-2159.
59. Humpl T, Reyes JT, Erickson S, Armano R, et al. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. Cardiol Young 2011; 21:187-193.
60. Jones HE, Kaltenbach K, Heil S, et al. Neonatal abstinence syndrome following methadone or buprenorphine exposure. New Engl J Med 2010; 363:2320-2331. [02]
61. Kellogg A, Rose CH, Harms RH,Watson WJ. Current trends in narcotic use in pregnancy and neonatal outcomes - art. no. 259.e1. Am J Obstet Gynecol 2011; 204:E1.
62. Kraft WK, Dysart K, Greenspan JS, et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011; 106:574-580. [48]
63. Kraft WK, Dysart K, Greenspan JS, Gibson E, et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011; 106:574-580.
64. Lester BM, Padbury JF. Third pathophysiology of prenatal cocaine exposure. Dev Neurosci 2009; 31:23-35. [26]
65. Raith W, Kutschera J, Muller W, Urlesberger B. Active Ear Acupuncture Points in Neonates with Neonatal Abstinence Syndrome (NAS). Am J Chin Med 2011;39:29-37.
66. Salisbury AL, Ponder KL, Padbury JF, Lester BM. Fetal effects of psychoactive drugs. Clin Perinatol 2009; 36:595-619. [27]
67. Williams F, Hume R. The measurement, definition, aetiology and clinical consequences of neonatal transient hypothyroxinaemia [Review]. Ann Clin Biochem 2011; 48:7-22.